Eduardo Martinez-Montes

Antonio Eduardo Arce

- Co-Diagnostics (CODX) presented its **CODX PCR Pro platform**, a compact, low-cost, smartphone-operated device designed for real-time PCR diagnostics, capable of delivering results in approximately **30 minutes** using its proprietary **CoPrimers technology** for multiplex testing.  **[1692415_2162801_1]** **[1692415_2162801_2]** **[1692415_2162801_3]** 
- The company is targeting significant market opportunities in the U.S., including physicians, urgent care facilities, pharmacies, skilled nursing facilities, and the home market.  **[1692415_2162801_3]** 
- Co-Diagnostics has a joint venture in India, established in **2017**, which has **15 authorized tests** with the CDSCO and recently opened a new oligonucleotide manufacturing facility. The focus in India includes **tuberculosis (TB)** and **human papillomavirus (HPV)** tests, with the CODX PCR Pro device costing **less than $1,000** compared to higher-priced alternatives.  **[1692415_2162801_4]** 
- The CODX PCR platform is currently undergoing FDA regulatory review and is not yet available for sale. The company's regulatory strategy includes seeking FDA clearance for a multiplex flu A/B/COVID-19/RSV test, as well as pursuing regulatory authority in India, South Africa, and Saudi Arabia.  **[1692415_2162801_1]** **[1692415_2162801_4]** **[1692415_2162801_5]**

Co-Diagnostics Showcases CODX PCR Pro Platform and Global Market Strategy

- Co-Diagnostics, Inc. (CODX) announced the **closing** of its registered direct offering on **September 18, 2025**.  **[1692415_20250918LA77466:0]** 
- The offering involved the sale of **9,619,000 shares** of common stock at an offering price of **$0.40 per share**.  **[1692415_20250918LA77466:0]** 
- The company received approximately **$3.8 million** in gross proceeds from the offering.  **[1692415_20250918LA77466:0]** 
- The proceeds are intended for **working capital and general corporate purposes**.  **[1692415_20250918LA77466:0]**

Co-Diagnostics Closes Registered Direct Offering

- Co-Diagnostics, Inc. priced a registered direct offering of **9,619,000 shares** of common stock at **$0.40 per share**.  **[1692415_0001493152-25-013981_ex99-1.htm:0]** **[1692415_0001493152-25-013981_form8-k.htm:1]** 
- The offering is expected to generate approximately **$3.8 million** in gross proceeds for the company.  **[1692415_0001493152-25-013981_ex99-1.htm:0]** **[1692415_0001493152-25-013981_form8-k.htm:1]** 
- The company intends to use the proceeds for **working capital and general corporate purposes**.  **[1692415_0001493152-25-013981_ex99-1.htm:0]** **[1692415_0001493152-25-013981_form8-k.htm:1]** 
- The offering is anticipated to close on or about **September 18, 2025**.  **[1692415_0001493152-25-013981_ex99-1.htm:0]** **[1692415_0001493152-25-013981_form8-k.htm:1]** 
- Co-Diagnostics has agreed to restrictions on issuing common stock or equivalents for **30 days** following the closing and has granted participation rights to investors for subsequent financing within 12 months.  **[1692415_0001493152-25-013981_form8-k.htm:1]** **[1692415_0001493152-25-013981_ex10-1.htm:29]**

Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering

- Co-Diagnostics, Inc. has entered into a securities purchase agreement for a registered direct offering of common stock.  **[1692415_20250917LA75875:0]** 
- The offering involves the sale of **9,619,000 shares** of common stock at an offering price of **$0.40 per share**.  **[1692415_20250917LA75875:0]** 
- The gross proceeds are estimated to be approximately **$3.8 million**, which the Company intends to use for **working capital and general corporate purposes**.  **[1692415_20250917LA75875:0]** 
- The offering is expected to close **on or about September 18, 2025**.  **[1692415_20250917LA75875:0]**

Co-Diagnostics Announces Pricing of Common Stock Offering

- **Co-Diagnostics, Inc.** (CODX) has signed a strategic **Memorandum of Understanding (MOU)** with a regional manufacturing and distribution company in the **Kingdom of Saudi Arabia (KSA)** to explore a joint venture.  **[1692415_20250916LA74199:0]** 
- This joint venture aims to develop, manufacture, and distribute **Co-Dx intellectual property**, including the upcoming **Co-Dx™ PCR platform**, throughout the **Middle East and North Africa (MENA)** region.  **[1692415_20250916LA74199:0]** 
- The KSA partner will provide **local operational support, infrastructure, personnel, and regulatory expertise**, with the JV's mission aligning with **KSA's Vision 2030** to potentially qualify for government incentives.  **[1692415_20250916LA74199:0]**